Draegerwerk Ag & Co. Kgaa · XETR:DRW8
Draegerwerk Ag & Co. Kgaa — Drägerwerk AG & Co. KGaA — Q1 2026 Earnings Presentation
41 slides from Draegerwerk Ag & Co. Kgaa's earnings presentation, Apr 30, 2026
Slide 1: Capital Markets Presentation
Capital Markets Presentation Drägerwerk AG & Co. KGaA April 2026, Lübeck Fußzeile: Bitte entsprechende Gesellschaft ergänzen
Slide 2: Disclaimer
Disclaimer — This presentation does not constitute an offer of securities for sale or a solicitation of an offer to purchase any securities. No money, securities or other consideration is being solicited by this presentation. This presentation contains forward-looking statements regarding the future
Slide 3: Content – Agenda
Content – Agenda — 01 Company 02 Financials 03 Outlook Drägerwerk AG & Co. KGaA 3
Slide 4: Dräger products protect, support and save lives
„Dräger products protect, support and save lifes.“ Stefan Dräger, Chairman of the Executive Board Drägerwerk AG & Co. KGaA 4
Slide 5: Company
01 Company Drägerwerk AG & Co. KGaA 5
Slide 6: Net sales development – Long-term growth
Net sales development – Long-term growth Corona 4.000 pandemic Ukraine war 3.500 Debt 3.000 crisis Financial 2.500 crisis Stock- market 2.000 Russian crash Mexican financial 1.500 peso crisis crisis 1.000 500 0 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2004 2001 2002 2003 2005 2006 2007
Slide 7: Dräger worldwide: Net sales, employees, sites
~43% ~57% Dräger worldwide Safety Division 16% 23% Medical Division Net sales, employees, sites 3.5 bn EUR net sales 21% 20251 40% ~59% ~18% Sales, Production, quality, 14% Marketing, logistics, purchasing service 16,687 14% employees 47% ~11% Research Headquarters 20251 and development Development
Slide 8: Our markets
Our markets Medical Technology Safety Technology Hospital Fire Services Oil and gas industry Mining Chemical industry Other markets Drägerwerk AG & Co. KGaA 8
Slide 9: Medical division
Medical division Operating Room Neonatal Care Intensive Care Hospital wide solutions Anaesthesiology Patient Monitoring & Clinical IT • Anaesthesia • Infinity Acute Care workstations and vaporizers • System Clincal software • #1 in Europe and solutions #2 in the US market • Telemetry and IT-
Slide 10: Safety division
Safety division Chemical Oil & Gas Mining Fire Service Other Markets Breathing Systems Impairment Check Equipment • Self-contained • Alcohol- and drug Breathing Appartus for fire fighters • screening devices Interlock devices • #2 worldwide and • #1 worldwide and #1 in Europe #1 in Europ
Slide 11: Medical and safety technology providing long-term growth prospects
Medical and safety technology providing long-term growth prospects Medical division Safety division • Average expected annual market growth for the global • Very diversified markets with numerous product and medical equipment market significantly exceeding service offerings Attractive growth prospec
Slide 12: Technology and innovation leadership to drive profitable growth
Technology and innovation leadership to drive profitable growth Strong R&D focus Innovation to enhance future growth (examples) • Approximately 1,900 employees in R&D around the globe. • EUR ~338 million spent for R&D costs in 2025.* • Very close collaboration with customers to develop new and impro
Slide 13: Exploit growth potentials in developing countries
Exploit growth potentials in developing countries • Focus on the specific needs of customer in developing countries Investments in profitable • Capitalize on the significant investments into the Sales & Service infrastructure and specific growth in developing market knowledge, especially in our Regi
Slide 14: Service- and consumables business a clear focus of our sales activities
Service- and consumables business a clear focus of our sales activities Further expansion of • Capitalize on large installed base to expand after sales business service and consumables • Focus on combined sale of equipment and after sales contracts business • Expansion of disposable consumables busi
Slide 15: Financials
02 Financials Drägerwerk AG & Co. KGaA 15
Slide 16: Business development Dräger Group – 5-year view
Business development Dräger Group – 5-year view Dräger Group 2021 2022 2023 2024 2025 Q1 2026 Q1 2025 € million € million € million € million € million € million € million Net sales 3,328 3,045 3,374 3,371 3,482 756 730 Change (nominal) -2.3% -8.5% 10.8% -0.1% 3.3% 3.5% -0.8% Change (net of currency
Slide 17: Key figures Dräger Group – 5-year view
Key figures Dräger Group – 5-year view Dräger Group 2021 2022 2023 2024 2025 Q1 2026 Q1 2025 Change € million € million € million € million € million € million € million % Cashflow (from operating activities) 385 -144 190 167 238 62 56 10.9 Investments 194 131 142 126 167 33 29 13.3 Cash and cash eq
Slide 18: Outlook
03 Outlook Drägerwerk AG & Co. KGaA 18
Slide 19: Outlook: Expectations for fiscal year 2026
Outlook Expectations for fiscal year 2026 Results achieved Current forecast for Indicator for fiscal year 2025 fiscal year 2026 Net sales (net of currency effects) 5.3% 2.0 to 6.0% EBIT margin 6.7% 5.0 to 7.5% Dräger Value Added (DVA) EUR 90.1 million EUR 20 to 120 million Drägerwerk AG & Co. KGaA 1
Slide 20: Outlook: Mid-term Corporate Objectives
Outlook 01 02 03 Mid-term Profitability first Innovation Leadership Competence in Inter- operability/System Business Corporate Priority has changed Revitalize our innovation, deploy — from revenue growth this strength successfully to our We enhance the level of Objectives towards profitability. mark
Slide 21: Technology for Life
Technology for Life Drager
Slide 22: Outlook: Expectations for fiscal year 2026
Outlook Expectations for fiscal year 2026 Results achieved Forecast for Indicator for fiscal year 2025 fiscal year 2026 Net sales (net of currency effects) 5.3% 2.0 to 6.0% EBIT margin 6.7% 5.0 to 7.5% DVA EUR 90.1 million EUR 20 to 120 million Gross margin 45.2% 44.0 to 46.0% R&D costs1 EUR 337.6 m
Slide 23: Management: The Dräger Executive Board
Management The Dräger Executive Board Stefan Dräger Gert-Hartwig Lescow Stefanie Hirsch Rainer Klug Dr. Reiner Piske Anton Schrofner Chairman of the Deputy Chairman of Executive Board Executive Board Executive Board Executive Board Executive Board - the Executive Board; Member for member for Safety
Slide 24: Dräger shares: Shareholder structure
Dräger shares Shareholder structure 10,160,000 Common shares (28.4% Free float) Free float 8,600,000 Preferred shares (100.0% Free float) 28.38% USA 29% Germany 46% Shareholding Shareholder structure 2 Common shares 1 Unknown investors Dräger family 1% 71.62% Rest of the Rest of Europe world 14% 10%
Slide 25: Business development Group / Division / Region
Business development Group / Division / Region Dräger Group 2022 2023 2024 2025 Q1 2026 Q1 2025 Change Change € million € million € million € million € million € million % nominal % fx-adj. Medical division 1,821.5 1,966.2 1,899.7 1,995.6 417.7 413.1 1.1 5.4 Safety division 1,223.7 1,407.3 1,471.2 1
Slide 26: Medical division Business development
Medical division Business development Medical division 2022 2023 2024 2025 Q1 2026 Q1 2025 Change Change € million € million € million € million € million € million % nominal % fx-adj. Net sales 1,821.5 1,966.2 1,899.7 1,995.6 417.7 413.1 1.1 5.4 Germany 367.5 402.7 406.8 435.0 101.5 99.2 2.3 2.3 EM
Slide 27: Safety division Business development
Safety division Business development Safety division 2022 2023 2024 2025 Q1 2026 Q1 2025 Change Change € million € million € million € million € million € million % nominal % fx-adj. Net sales 1,223.7 1,407.3 1,471.2 1,486.3 338.2 317.2 6.6 8.8 Germany 298.0 345.6 369.0 369.4 83.5 77.4 8.0 8.0 EMEA
Slide 28: Functional expenses Dräger Group – 5-year view
Functional expenses Dräger Group – 5-year view Dräger Group 2021 2022 2023 2024 2025 Q1 2026 Q1 2025 Change € million € million € million € million € million € million € million % R&D 328.6 343.5 325.4 333.1 333.8 79.8 83.6 -4.5 % of net sales 9.9% 11.3% 9.6% 9.9% 9.6% 10.6% 11.4% Sales & Marketing
Slide 29: Cash flow statement Dräger Group – 5-year view
Cash flow statement Dräger Group – 5-year view Dräger Group 2021 2022 2023 2024 2025 Q1 2026 Q1 2025 Change € million € million € million € million € million € million € million % Group net profit 154.3 -63.6 112.0 124.8 140.4 11.3 -1.9 >+100 Change in inventories 14.4 -81.8 13.0 -6.2 2.9 -66.2 -60.
Slide 30: Balance sheet (assets) Group 12M
Balance sheet (assets) Group 12M Assets 12.2025 12.2024 Change € million € million % Intangible assets 336.2 342.8 -1.9 Property, plant and equipment (incl. Right-of-use-assets) 559.5 549.0 1.9 Other noncurrent assets 352.9 316.8 11.4 Noncurrent assets 1,248.5 1,208.7 3.3 Inventories 629.0 662.6 -5.
Slide 31: Balance sheet (equity and liabilities) Group 12M
Balance sheet (equity and liabilities) Group 12M Equity and liabilities 12.2025 12.2024 Change € million € million % Equity 1,628.7 1,536.8 6.0 Provisions for pensions and similar obligations 152.2 180.4 -15.6 Noncurrent personnel provisions 37.6 36.6 2.8 Noncurrent interest bearing loans 153.7 104.
Slide 32: Business development Dräger Group – 5 years
Business development Dräger Group – 5 years — Order intake1 Net sales1 EBIT1 (margin) fx-adj. -17.9% +2.9% +2.2% +3.4% +7.7% -1.8% -11.5% +13.1% +0.5% +5.3% (8.2%) (-2.9%) (4.9%) (5.8%) (6.7%) nominal -18.4% +6.4% +0.2% +2.8% +5.6% -2.3% -8.5% +10.8% -0.1% +3.3% CAGR +1.1 % 3,569 3,482 272 3,285 3,2
Slide 33: Business development Dräger Group – 5 years
Business development Dräger Group – 5 years — DVA1 Equity1 (ratio) Net financial debt1 (/EBITDA) (39.7%) (42.5%) (45.5%) (49.7%) (51.5%) (-0.06) (4.64) (0.63) (0.49) (0.33) 172 1,629 259 1,537 1,409 1,261 1,319 198 165 90 123 56 54 -196 -24 2021 2023 2024 2025 2021 2022 2023 2024 2025 2022 2023 2024
Slide 34: Business development Medical division – 5 years
Business development Medical division – 5 years — Order intake1 Net sales1 EBIT1 (margin) fx-adj. -22.6% -0.5% -1.3% +1.2% +8.9% -9.7% -15.0% +10.3% -2.7% 7.4% (9.3%) (-5.0%) (1.9%) (1.5%) (2.9%) nominal -23.3% +3.3% -3.2% +0.4% +6.4% -10.3% -11.8% +7.9% -3.4% 5.0% CAGR +1.7% CAGR -0.8% 2,047 2,064
Slide 35: Business development Safety division – 5 years
Business development Safety division – 5 years — Order intake1 Net sales1 EBIT1 (margin) fx-adj. -8.8% +8.4% +7.4% +6.4% +6.1% +14.5% -5.8% +17.2% +4.9% +2.6% (6.3%) (0.1%) (9.2%) (11.3%) (11.9%) nominal -9.1% +11.5% +5.2% +6.0% +4.6% +14.5% -3.2% +15.0% +4.5% +1.0% 1.523 1.471 1.486 176 1.456 1.407
Slide 36: Dividend policy
Dividend policy Dräger intends to continue distributing at least 30% of consolidated annual net profit in the coming years, provided that the Group's equity ratio is at least 40%. — Total distribution1 (rate) Dividend (yield) per Dividend (yield) per common share2 preferred share2 (2.4%) (-5.7%) (30
Slide 37: Sustainability Ratings
Sustainability Ratings — Rating agency Overall rating Further information Ecovadis 73 out of 100 points (silver medal) Dräger is among the top 15 % of the companies assessed by Ecovadis. C+ on a scale from AAA (Leader) to CCC (Laggard) Dräger has a “very high” transparency level. 56.67 points (Prime
Slide 38: Silent ICU
Muting and Analgesia forwarding control alarms Gentle ventilation and weaning Patient monitoring Silent ICU • Concept for alarm forwarding and muting of medical devices with Service-oriented Device Connectivity (SDC) • Information flows bi-directionally across manufacturers with SDC • Patient device
Slide 39: Financial calendar Events
Financial calendar Events Dräger publishes preliminary results approximately 2 weeks before the dates of the quarterly reports. Preliminary results for the full year are published in January. March 24, 2026 Annual Report 2025 Conference Call April 30, 2026 Report for the first three months 2026 Conf
Slide 40: Contact
Contact Visit our Investor Relations website: https://www.draeger.com/en-us_us/Investor-Relations Thomas Fischler | Head of Treasury & Investor Relations Moislinger Alle 53-55 23558 Lübeck, Germany Tel. +49 451 882 2685 Mail: thomas.fischler@draeger.com Nikolaus Hammerschmidt | Investor Relations Ma
Slide 41: Thank you
Thank you Drägerwerk AG & Co. KGaA 41
Drägerwerk AG & Co. KGaA — Q1 2026 Earnings Presentation on 6ix